Ursula Hasler-Strub

Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis

Bernhard Hess, Ursula Hasler-Strub, Daniel Ackermann et al. · Nephrology Dialysis Transplantation · 1997 · 95 citations · Full text

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08

Khalil Zaman, Christoph Mamot, Ursula Hasler-Strub et al. · European Journal of Cancer · 2015 · 50 citations

Breast Cancer Progressing, Breast Oncology, Oncology +11

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

Christoph Rochlitz, Martin Bigler, Roger von Moos et al. · BMC Cancer · 2016 · 46 citations · Full text

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer

Christoph Mamot, Andreas Wicki, Ursula Hasler-Strub et al. · Scientific Reports · 2023 · 38 citations · Full text

Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).

Florence Joly, Isabelle Laure Ray-Coquard, María Jesús Rubio et al. · Journal of Clinical Oncology · 2023 · 20 citations

Mmr Deficient, Clinical Endpoint, Gynecology +16